Positions

Overview

  • Dr. Hoesley received his medical degree from the University of South Florida and completed his internship, internal medicine residency, chief residency, and infectious disease fellowship at the University of Alabama at Birmingham. He joined the UAB faculty in 1999 and served as the internal medicine clerkship director for 7 years prior to becoming the associate dean for undergraduate medical education in 2008. In July 2015, Dr. Hoesley became the senior associate dean for medical education and chair of the Department Medical Education. In this role, he provides oversight for the undergraduate and graduate medical education programs as well as continuing medical education and medical student services in the School of Medicine.

    His research interests include the development of a safe and effective microbicide to prevent sexual transmission of HIV. He is the UAB site leader for the NIH-funded Microbicide Trials Network. Dr. Hoesley is the current chair of the University Hospital Pharmacy and Therapeutic Committee.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal RingsClinical Infectious Diseases.  68:1136-1143. 2019
    2019 Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal WomenClinical Infectious Diseases.  68:1144-1151. 2019
    2019 Pharmacokinetics of dapivirine transfer into blood plasma, breast milk, and cervicovaginal fluid of lactating women using the dapivirine vaginal ringAntimicrobial Agents and Chemotherapy2019
    2019 A Mixed-Methods Study Examining Adherence to and Acceptability of Intravaginal Rings for HIV Prevention: Behavioral Results of MTN-027AIDS and Behavior2019
    2018 Improvement of gram-negative susceptibility to fluoroquinolones after implementation of a pre-authorization policy for fluoroquinolone use: A decade-long experienceInfection Control and Hospital Epidemiology.  39:1419-1424. 2018
    2016 First-in-human trial of MIV-150 and zinc acetate coformulated in a carrageenan gel: Safety, pharmacokinetics, acceptability, adherence, and pharmacodynamicsJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology.  73:489-496. 2016
    2016 Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United StatesAIDS and Behavior.  20:2644-2653. 2016
    2016 In vitro exposure to PC-1005 and cervicovaginal lavage fluid from women vaginally administered PC-1005 inhibits HIV-1 and HSV-2 infection in human cervical mucosaAntimicrobial Agents and Chemotherapy.  60:5459-5466. 2016
    2016 Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trialMedicine.  95. 2016
    2016 Evaluation of baseline corrected QT interval and azithromycin prescriptions in an academic medical centerJournal of Hospital Medicine.  11:15-20. 2016
    2015 Mucosal effects of tenofovir 1% geleLife.  2015:1-49. 2015
    2015 Integration of gross anatomy in an organ system-based medical curriculum: Strategies and challengesAnatomical Sciences Education.  8:266-274. 2015
    2015 Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: A double-blind randomized trialJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology.  70:242-249. 2015
    2014 Barrier Methods for Human Immunodeficiency Virus PreventionInfectious Disease Clinics of North America.  28:585-599. 2014
    2014 A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012/IPM 010)AIDS Research and Human Retroviruses.  30:184-189. 2014
    2013 A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)PLoS ONE.  8. 2013
    2013 Adherence and acceptability in MTN 001: A randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in womenAIDS and Behavior.  17:737-747. 2013
    2013 MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other CompartmentsPLoS ONE.  8. 2013
    2010 Anal-rectal cytology: Correlation with human papillomavirus status and biopsy diagnoses in a population of HIV-positive patientsJournal of Lower Genital Tract Disease.  14:90-96. 2010
    2010 Human immunodeficiency virus infection in alabama women: Sociodemographic, behavioral, and reproductive health characteristics and factors associated with lack of Human immunodeficiency virus-1 viral controlAmerican Journal of the Medical Sciences.  339:133-140. 2010
    2010 University of Alabama School of MedicineAcademic Medicine.  85. 2010
    2009 Internal medicine clerkship characteristics associated with enhanced student examination performanceAcademic Medicine.  84:895-901. 2009
    2009 Novel methodology for antiretroviral quantitation in the female genital tractHIV Clinical Trials.  10:193-199. 2009
    2008 Emergence of USA300 MRSA in a tertiary medical centre: implications for epidemiological studiesJournal of Hospital Infection.  68:208-213. 2008
    2008 Dissemination of community-associated methicillin-resistant Staphylococcus aureus in a tertiary care hospitalSouthern Medical Journal.  101:40-45. 2008
    2007 USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical site infectionsJournal of Clinical Microbiology.  45:3431-3433. 2007
    2006 Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical centerJournal of Clinical Microbiology.  44:3368-3370. 2006
    2006 Prevalence of inducible clindamycin resistance among community- and hospital-associated Staphylococcus aureus isolatesJournal of Clinical Microbiology.  44:2481-2484. 2006
    2006 Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected womenAIDS.  20:1109-1116. 2006
    2005 Trends in cancer incidence rates among HIV-infected patients [3] (multiple letters)Clinical Infectious Diseases.  41:124-127. 2005
    2004 Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002Clinical Infectious Diseases.  39:1380-1384. 2004
    2004 High-risk human papillomavirus and cervical intraepithelial neoplasia at time of atypical squamous cells of undetermined significance cytologic results in a population with human immunodeficiency virusJournal of Lower Genital Tract Disease.  8:298-303. 2004
    2004 University of alabama school of medicine.Academic Medicine.  79:S1-S2. 2004
    2004 University of alabama school of medicine.Academic Medicine.  79. 2004
    2004 Incidence and risk factors for sexually transmitted infections among women in an Alabama HIV clinicAIDS Research and Human Retroviruses.  20:577-583. 2004
    2003 A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: Correlations with CD4 cell count and plasma HIV-1 RNA levelClinical Infectious Diseases.  36:207-211. 2003
    2002 Comparative analysis of commercial assays for the detection and quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype CClinical Infectious Diseases.  35:323-325. 2002
    2001 Viral latency--the papillomavirus model.Developments in Biological Standardization.  106. 2001
    2000 Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practiceClinical Infectious Diseases.  31:1095-1097. 2000
    1998 Use of statistics and scientific inference: Odds ratios, likelihood ratio, and receiving operating characteristic curves [2] (multiple letters)Journal of Infectious Diseases.  178:921-923. 1998

    Chapter

    Year Title Altmetric
    2010 Bartonellosis (carrión’s disease).  903-904. 2010

    Principal Investigator On

  • Leadership and Operations Center (LOC): Microbicide Trials Network - Protocol Funds MTN 038  awarded by Magee-Womens Research Institute (MWRI) 2018 - 2019
  • Leadership and Operations Center (LOC): Microbicide Trials Network - Protocol Funds: MTN-037  awarded by Magee-Womens Research Institute (MWRI) 2018 - 2019
  • Leadership and Operations Center (LOC): Microbicide Trials Network - Protocol Funds MTN-035  awarded by Magee-Womens Research Institute (MWRI) 2018 - 2019
  • Leadership and Operations Center (LOC): Microbicide Trials Network - Protocol Funds: MTN -038  awarded by Magee-Womens Research Institute (MWRI) 2017 - 2018
  • MTN 035 Acceptability, Tolerability, and Adherence Of Three Rectal Microbicide Dosage Forms Among HIV Seronegative Men And Transgender Women  awarded by Magee-Womens Research Institute (MWRI) 2017 - 2018
  • MTN 037 Protocol Funds  awarded by Magee-Womens Research Institute (MWRI) 2017 - 2018
  • Leadership and Operations Center (LOC): Microbicide Trials Network (MTN 036 Protocol Funds)  awarded by Magee-Womens Research Institute (MWRI) 2016 - 2018
  • Leadership and Operations Center (LOC): Microbicide Trials Network - MTN 030  awarded by Magee-Womens Research Institute (MWRI) 2016 - 2018
  • MTN 026 Protocol Funds  awarded by Magee-Womens Research Institute (MWRI) 2015 - 2018
  • Leadership and Operations Center (LOC): Microbicide Trials Network  awarded by Magee-Womens Research Institute (MWRI) 2014 - 2017
  • Leadership and Operations Center (LOC): Microbicide Trials Network, MTN-029  awarded by Magee-Womens Research Institute (MWRI) 2015 - 2016
  • Equal Access Birmingham I-Stat Grant  awarded by Community Foundation of Greater Birmingham 2015 - 2016
  • Leadership and Operations Center (LOC): Microbicides Trials Network  awarded by Magee-Womens Research Institute (MWRI) 2014 - 2015
  • Equal Access Birmingham Dispensary Funding  awarded by Community Foundation of Greater Birmingham 2013 - 2015
  • PC-558 A Phase 1, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Acceptibility of PC-1005 (MIV-150/ZA in a Carrageenan Vehicle) Microbicide Gel Formulation in HIV- Seronegative Women  awarded by Population Council 2014 - 2015
  • A Double-Blind, Randomized, Placebo-Controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel 4759, 0/05% 2.5g and Dapivirine Gel 4789, 0.05% 2.5g Formulations as Compared to the Vaginal Hec-Based Universal Placebo Gel, 2.5g in Healthy HIV-Negative Women  awarded by INTERNATIONAL PARTNERSHIP FOR MICROBICIDES, INC. 2009 - 2011
  • Teaching Activities

  • 06-299A - EAB PATIENT PANEL ASSOCIATE (Spring Term 2018) 2018
  • STP299AV - Comparison of International Medical Education in the Netherlands (Fall Term 2017) 2017
  • STP2999FL - MY PATH TO MEDICAL SCHOOL AND MY FUTURE CAREER (Spring Term 2017) 2017
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2015) 2015
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2015) 2015
  • STP2999CZ - CDC: INFECTIOUS DISEASE DATABASE DEVELOPMENT (Fall Term 2015) 2015
  • STP2147 - MENTAL HEALTH MANAGEMENT AND CLINICAL SKILLS (Fall Term 2015) 2015
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2015) 2015
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2015) 2015
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2015) 2015
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2015) 2015
  • STP2147 - MENTAL HEALTH MANAGEMENT AND CLINICAL SKILLS (Fall Term 2015) 2015
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2015) 2015
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2015) 2015
  • STP2147 - MENTAL HEALTH MANAGEMENT AND CLINICAL SKILLS (Fall Term 2015) 2015
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2015) 2015
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2015) 2015
  • PUH697 - Practice Placement (Fall Term 2014) 2014
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2014) 2014
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2014) 2014
  • STP2147 - MENTAL HEALTH MANAGEMENT AND CLINICAL SKILLS (Fall Term 2014) 2014
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2014) 2014
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2014) 2014
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2014) 2014
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2014) 2014
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2014) 2014
  • STP2147 - MENTAL HEALTH MANAGEMENT AND CLINICAL SKILLS (Fall Term 2014) 2014
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2014) 2014
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2014) 2014
  • STP2147 - MENTAL HEALTH MANAGEMENT AND CLINICAL SKILLS (Fall Term 2014) 2014
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2014) 2014
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2014) 2014
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2013) 2013
  • STP2143 - EAB CLINICAL MANAGEMENT (Fall Term 2013) 2013
  • STP2142 - EAB CLINICAL SKILLS (Fall Term 2013) 2013
  • 95-406 - CLINICAL PATHOLOGY (Fall Term 2012) 2012
  • 06-402E - BASIC SCIENCE ELECTIVE (Fall Term 2011) 2011
  • 06-402E - BASIC SCIENCE ELECTIVE (Fall Term 2011) 2011
  • 06-402E - BASIC SCIENCE ELECTIVE (Fall Term 2011) 2011
  • 06-402E - BASIC SCIENCE ELECTIVE (Fall Term 2011) 2011
  • 06-402E - BASIC SCIENCE ELECTIVE (Spring Term 2011) 2011
  • 06-402E - BASIC SCIENCE ELECTIVE (Spring Term 2011) 2011
  • 06-402E - BASIC SCIENCE ELECTIVE (Spring Term 2011) 2011
  • 06-402E - BASIC SCIENCE ELECTIVE (Spring Term 2011) 2011
  • 06-402E - BASIC SCIENCE ELECTIVE (Spring Term 2011) 2011
  • 06-402E - BASIC SCIENCE ELECTIVE (Spring Term 2011) 2011
  • STP2102 - OREGON SEARCH PROGRAM (Fall Term 2010) 2010
  • STP2103 - OREGON SEARCH PROGRAM (Fall Term 2010) 2010
  • STP2999 - SPECIAL TOPIC EXPERIENCE (Fall Term 2010) 2010
  • 06-402E - BASIC SCIENCE ELECTIVE (Spring Term 2010) 2010
  • 06-402E - BASIC SCIENCE ELECTIVE (Spring Term 2010) 2010
  • 10-458 - PREPARATION FOR INTERNSHIP AND RESIDENCY TRAINING (Spring Term 2008) 2008
  • 28-422 - INFECTIOUS DISEASES (Spring Term 2008) 2008
  • 28-422 - INFECTIOUS DISEASES (Spring Term 2008) 2008
  • 28-517 - MEDICINE RESEARCH (Spring Term 2008) 2008
  • 28-422 - INFECTIOUS DISEASES (Spring Term 2008) 2008
  • 28-422 - INFECTIOUS DISEASES (Spring Term 2008) 2008
  • 28-517 - MEDICINE RESEARCH (Fall Term 2007) 2007 - 2008
  • 28-422 - INFECTIOUS DISEASES (Fall Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Fall Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Fall Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Fall Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Fall Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Fall Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Fall Term 2007) 2007
  • 28-517 - MEDICINE RESEARCH (Fall Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Fall Term 2007) 2007
  • 28-517 - MEDICINE RESEARCH (Fall Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Fall Term 2007) 2007
  • 28-517 - MEDICINE RESEARCH (Fall Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Fall Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Fall Term 2007) 2007
  • 02-280 - MEDICINE CLERKSHIP (Spring Term 2007) 2007
  • 10-458 - PREPARATION FOR INTERNSHIP AND RESIDENCY TRAINING (Spring Term 2007) 2007
  • 02-280 - MEDICINE CLERKSHIP (Spring Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Spring Term 2007) 2007
  • 28-517 - MEDICINE RESEARCH (Spring Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Spring Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Spring Term 2007) 2007
  • 02-280 - MEDICINE CLERKSHIP (Spring Term 2007) 2007
  • 28-422 - INFECTIOUS DISEASES (Spring Term 2007) 2007
  • Education And Training

  • Doctor of Medicine, University of South Florida 1992
  • Bachelor of Science or Mathematics in Biology, University of South Florida 1987
  • UAB Hospital, Internship 1993
  • UAB Hospital, Residency 1995
  • UAB Hospital, Postdoctoral Fellowship 1998
  • Full Name

  • Craig Hoesley